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Aberrant activation of Janus kinase 2 (JAK2) caused by somatic
mutation of JAK2 (JAK2V617F) or the thrombopoietin receptor
(MPLW515L) plays an essential role in the pathogenesis of
myeloproliferative neoplasms (MPNs), suggesting that inhibi-
tion of aberrant JAK2 activation would have a therapeutic
beneﬁt. Our novel JAK2 inhibitor, NS-018, was highly active
against JAK2 with a 50% inhibition (IC50)o fo1n M, and had
30–50-fold greater selectivity for JAK2 over other JAK-family
kinases, such as JAK1, JAK3 and tyrosine kinase 2. In addition
to JAK2, NS-018 inhibited Src-family kinases. NS-018 showed
potent antiproliferative activity against cell lines expressing a
constitutively activated JAK2 (the JAK2V617F or MPLW515L
mutations or the TEL–JAK2 fusion gene; IC50¼11–120nM), but
showed only minimal cytotoxicity against most other hemato-
poietic cell lines without a constitutively activated JAK2.
Furthermore, NS-018 preferentially suppressed in vitro erythro-
poietin-independent endogenous colony formation from
polycythemia vera patients. NS-018 also markedly reduced
splenomegaly and prolonged the survival of mice inoculated
with Ba/F3 cells harboring JAK2V617F. In addition, NS-018
signiﬁcantly reduced leukocytosis, hepatosplenomegaly and
extramedullary hematopoiesis, improved nutritional status, and
prolonged survival in JAK2V617F transgenic mice. These
results suggest that NS-018 will be a promising candidate for
the treatment of MPNs.
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Introduction
The breakpoint cluster region-abelson (BCR-ABL)-negative
myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia and primary myelo-
ﬁbrosis.
1,2 Current treatment options for MPNs, and especially
for primary myeloﬁbrosis, are limited and largely palliative with
the notable exception of allogeneic stem cell transplantation.
3
A somatic point mutation at codon 617 of Janus kinase 2 (JAK2)
tyrosine kinase (TYK) (JAK2V617F) has been shown to occur
in B95% of patients with PV and B50% of patients with
essential thrombocythemia and primary myeloﬁbrosis.
4–8
JAK2V617F is a constitutively activated kinase that activates
the JAK/STAT signaling pathway and dysregulates cell growth
and function. Expression of JAK2V617F transforms hemato-
poietic cells to cytokine-independent growth in vitro and causes
MPN-like diseases in mice after bone marrow transplanta-
tion.
5,9–12 Transgenic mice expressing JAK2V617F also develop
MPN-like diseases.
13–18 In addition, other somatic mutations
leading to aberrant JAK2 activation, that is, activating mutations
in exon 12 of JAK2 and mutations at codon 515 of the thrombo-
poietin receptor (MPLW515L/K), have been identiﬁed in
JAK2V617F-negative MPN patients.
19,20 These ﬁndings suggest
that the inhibition of aberrant JAK2 activation would have a
therapeutic beneﬁt, and several JAK2 inhibitors are currently in
clinical trials for patients with MPNs.
21,22
NS-018 is a newly discovered, orally bioavailable, small-
molecule inhibitor of JAK2 that is competitive with adenosine
triphosphate (ATP). In this study, we describe the preclinical
characterization of NS-018 and report on its potent and selective
inhibitory activity against JAK2 and Src-family kinases and
promising in vitro and in vivo activity against constitutively
active JAK2 mutants.
Materials and methods
Structural analysis
The kinase domain of human JAK2 was expressed in Sf9 cells
infected with recombinant virus and puriﬁed as described
elsewhere.
23 The NS-018/protein complex was concentrated
and crystallized by the hanging drop method at 41C. Diffraction
data from ﬂash-frozen crystals were collected at the BL32B2
beamline of the SPring-8 synchrotron facility (Hyogo, Japan)
and processed with the HKL-2000 package.
24 The structure
was solved by molecular replacement with the program
Phaser.
25 All computations were performed with Molecular
Operating Environment version 2009.10 (Chemical Computing
Group, Montreal, QC, Canada). Figure 1 was prepared with
PyMOL version 1.3 (Schro ¨dinger, New York, NY, USA).
In vitro kinase assay
The kinase domains of human JAK1, JAK2, JAK3 and TYK2 were
purchased from Carna Biosciences (Kobe, Japan). Each kinase
was incubated in a reaction medium containing serial dilutions
of NS-018, biotinylated peptide substrate, ATP and MgCl2 in a
streptavidin-coated plate for 1h at 301C. Phosphorylated
substrates were spectrophotometrically detected with horse-
radish peroxidase-linked antibody (PY-20; BD Biosciences,
San Jose, CA, USA) and TMB (3,30,5,50-tetramethylbenzidine)
solution (Sigma Aldrich, St Louis, MO, USA). The concentrations
required to give 50% inhibition (IC50) were estimated by ﬁtting
the absorbance data to a logistic curve with SAS version 8.2
(SAS Institute, Cary, NC, USA). The inhibitory effect of NS-018
was tested against a panel of 53 kinases by Carna Biosciences
according to their internal protocol.
Cellular assay
Cell lines were used after reaching 70–90% conﬂuence. For cell
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1 10
3cells/well, SET-2 cells at 1 10
4cells/well, MV4-11cells
at 2 10
4cells/well and other cell lines at 5 10
3cells/well).
The next day, cells were treated with serial dilutions of NS-018,
and incubated for 72h at 371C with 5% CO2. Viability was
measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay. IC50 values were estimated with
SAS version 8.2. For western blotting and apoptosis, see
Supplementary Materials and methods.
Colony formation assay
Peripheral blood mononuclear cells from PV patients with the
JAK2V617F mutation or healthy volunteers were collected with
informed consent and Institutional Review Board approval. A
total of 2 10
5cells were treated with increasing concentrations
of NS-018 in MethoCult H4534 methylcellulose medium
(StemCell Technologies, Vancouver, BC, Canada) supplemented
with or without 3U/mL erythropoietin. Experiments were
performed in triplicate. Burst-forming unit-erythroids were
counted on day 14. IC50 values were estimated with SAS
version 8.2.
Mouse Ba/F3-JAK2V617F disease model
The study was conducted in compliance with the Law for the
Humane Treatment and Management of Animals (Law No. 105,
1973, as revised on 1 June 2006). Female BALB/c nude mice
(Japan SLC, Shizuoka, Japan) were placed in blanket cages in an
environment maintained at 21–251C and 45–65% relative
humidity, with artiﬁcial illumination for 12h and a ventilation
frequency of at least 15times/h. They were allowed free access
to food pellets and tap water. Ba/F3-JAK2V617F cells (10
6 per
mouse) were inoculated intravenously into 7-week-old mice.
Administration of vehicle (0.5% methylcellulose) or NS-018
twice daily by oral gavage began the day after cell inoculation.
Survival was monitored daily, and moribund mice were
humanely killed and their time of death was recorded for
purposes of survival analysis. In a parallel study, all mice were
humanely killed after 8 days of administration, and their spleens
were removed and weighed.
JAK2V617F transgenic mice
The generation and genotyping of transgenic mice (BDF1 strain)
were carried out as described previously.
15 At 12 weeks after
birth, treatment with vehicle or NS-018 was begun by oral
gavage and was continued twice a day on weekdays for
24 weeks. The body weight of the mice was measured weekly.
Peripheral blood was drawn monthly into heparin-coated glass
capillary tubes, and hematological parameters were determined
with a Celltac-a hematology analyzer (Nihon Kohden, Tokyo,
Japan). For fractional analysis of white blood cells (WBCs),
nucleated cells were stained with ﬂuorescently conjugated
antibodies speciﬁc for Mac1, Gr1, B220 and CD3 (BD
Biosciences) and the percentage of each fraction was deter-
mined with a FACSCalibur (BD Biosciences). The fractional cell
number was computed by multiplying the percentage by the
total WBC count.
All mice were humanely killed at the end of treatment, and
terminal blood samples and organs were collected. For ﬂow
cytometric analysis of spleen and bone marrow, see Supple-
mentary Materials and methods. For histological evaluation,
tissues samples from liver, spleen, lung and femur were ﬁxed in
formalin, embedded in parafﬁn and cut for hematoxylin-eosin
staining or Gomori silver staining according to standard
protocols (Biopathology Institute, Oita, Japan). Histological
slides were viewed under a BX50 microscope and photographed
with a FX380 digital camera (Olympus, Tokyo, Japan).
Results
NS-018 is a potent and selective JAK2 kinase inhibitor
in vitro
NS-018 was discovered by screening for potent and selective
JAK2 inhibitors. Structure-activity studies leading to the identi-
ﬁcation of NS-018 as a promising candidate and a description of
its synthesis will be published elsewhere. In in vitro kinase
assays, NS-018 was highly active against JAK2 with an IC50 of
0.72nM, and it had 30–50-fold greater selectivity for JAK2 over
other Jak-family kinases such as JAK1, JAK3 and TYK 2 (Table 1).
The ability of NS-018 to inhibit other kinases was tested with
a panel of 53 kinases in the presence of ATP at concentra-
tions close to their respective Km values. NS-018 showed potent
inhibition of Src-family kinases, notably SRC and FYN, as
well as weak inhibition of ABL and FLT3 with 45- and 90-fold
selectivity for JAK2, respectively (Table 2). NS-018 showed a
high degree of selectivity for JAK2 over many other TYKs
(Table 2) and serine/threonine kinases (Supplementary Table 1).
Structural analysis of JAK2 kinase in complex with
NS-018
Phosphorylation of the activation loop (A-loop) is one of the
most common mechanisms for regulating protein kinase
activity, and it leads to the relocation of an Asp–Phe–Gly
(DFG) motif located adjacent to the N-terminus of the
A-loop.
26 The X-ray co-crystal structure of JAK2 in complex
with NS-018 revealed that (1) Tyr residues at positions 1007 and
1008 in the A-loop were phosphorylated, (2) the phosphorylated
Figure 1 X-ray co-crystal structure of NS-018 bound to JAK2 kinase.
The surface of NS-018 is shown in pink, the backbone of JAK2 in slate,
and the A-loop in cyan. Gly993 is located immediately N-terminal to
the DFG motif. For clarity, only key residues are shown.
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JAK2 in the ‘DFG-in’ active conformation (Figure 1).
NS-018 inhibits JAK2-mediated signaling and
proliferation and induces apoptosis
To evaluate the effects of NS-018 on JAK2-mediated signal-
ing, we exposed Ba/F3 cells expressing JAK2V617F (Ba/F3-
JAK2V617F) to increasing concentrations of NS-018 for 3h and
measured the level of phosphorylation of JAK2-mediated
signaling components by western blotting (Figure 2a). NS-018
inhibited the phosphorylation of STAT5, STAT3 and ERK in a
dose-dependent manner, with maximal effects at B100nM,
30nM and 300nM, respectively.
We next assessed the antiproliferative activity of NS-018
against hematopoietic cell lines (Table 3). NS-018 suppressed
the growth of Ba/F3-JAK2V617F cells with an IC50 of 60nM and
the JAK2V617F-positive cell line SET-2 with an IC50 of 120nM.
NS-018 also inhibited the growth of Ba/F3-MPLW515L cells,
which is dependent on JAK2-mediated signaling due to an
activating mutation of the thrombopoietin receptor, at similar
concentrations. Ba/F3-TEL-JAK2 cells were highly sensitive to
NS-018, but Ba/F3-TEL-JAK3 cells were less sensitive. CMK
cells, which are dependent on both JAK1 and JAK3 because of
an activating mutation of JAK3 that signals through wild-type
JAK1,
27 were also insensitive to NS-018. NS-018 showed
weak antiproliferative activity against K-562 cells, which carry
BCR-ABL and MV4-11 cells, which carry an internal tandem
duplication of FLT3. This selective antiproliferative activity was
roughly consistent with the kinase inhibitory proﬁle of NS-018.
Additionally, NS-018 showed only minimal cytotoxicity against
other hematopoietic cell lines, such as SKM-1 and U-937.
To determine whether the antiproliferative activity of NS-018
was accompanied by an increase in apoptosis, we exposed Ba/
F3-JAK2V617F cells to various concentrations of NS-018 and
determined the percentages of apoptotic cells by ﬂow cytometry
with annexin V/propidium iodide staining and assessed DNA
fragmentation. NS-018 treatment increased both the percentage
of annexin V-positive cells (Figure 2b) and the extent of DNA
fragmentation (Figure 2c) in a dose-dependent manner. Thus,
NS-018 both inhibited the phosphorylation of components of
JAK2-mediated signaling and induced apoptosis in cell lines
whose growth depended on JAK2 activation.
NS-018 inhibits erythroid progenitor cell growth in
primary PV patient samples
To evaluate the efﬁcacy of NS-018 against primary MPN patient
cells, we performed colony formation assays with mononuclear
cells from the peripheral blood of PV patients with the
JAK2V617F mutation or of healthy volunteers. NS-018 inhibited
the formation of burst-forming unit-erythroid from healthy
controls and PV patients in a dose-dependent manner, but
the degree of inhibition was signiﬁcantly greater for the PV
patients (P¼0.011). Speciﬁcally, for three healthy controls,
NS-018 inhibited erythroid colony growth with a mean IC50 of
952±118nM, whereas for four PV patients the corresponding
IC50 was 529±36nM (Figure 3a). We also assessed the efﬁcacy
of NS-018 in inhibiting the growth of erythropoietin-indepen-
dent, endogenous erythroid colony formation, a hallmark of
JAK2V617F-positive MPN. NS-018 inhibited endogenous
erythroid colony formation with a mean IC50 of 224±26nM
(Figure 3b). Thus, NS-018 effectively inhibited erythroid pro-
genitor cell growth in PV patient samples.
NS-018 is effective in a mouse Ba/F3-JAK2V617F
disease model
We next evaluated the in vivo efﬁcacy of NS-018 in a mouse
acute disease model. Mice inoculated with Ba/F3-JAK2V617F
cells showed marked splenomegaly and died within 2–3 weeks
because of penetrant hematopoietic disease progression. NS-018,
administered by oral gavage twice a day, signiﬁcantly prolonged
survival of the mice at dosages of 12.5mg/kg or higher (Figure 4a).
Although vehicle-treated mice had all died by day 19, all mice
treated with 100mg/kg NS-018 were still alive even on day 25.
NS-018 also signiﬁcantly reduced splenomegaly at dosages of
1.5mg/kg or higher (Figure 4b). The weight and appearance of the
spleens of mice treated with 50mg/kg NS-018 were similar to
those of uninoculated control mice. Thus, NS-018 was highly
efﬁcacious in this mouse model of acute disease.
Efﬁcacy of NS-018 in mouse MPN model (JAK2V617F
transgenic mice)
Mice expressing JAK2V617F under the control of the H2Kb
promoter (V617F-transgenic mice (TG)) show an MPN
Table 1 In vitro effects of NS-018 on Jak-family enzyme activity
IC50 (nm) Fold selectivity over JAK2
JAK2 0.72 1
JAK1 33 46
JAK3 39 54
TYK2 22 31
Abbreviations: JAK, Janus kinase; TYK, tyrosine kinase.
Table 2 Tyrosine kinase selectivity proﬁle of NS-018
Tyrosine
kinase
Family
name
Inhibition at
100nm, %
Fold selectivity
over JAK2
JAK2 Jak 101.6 1
FYN Src 100.0 4
SRC Src 100.6 5
YES Src 100.1 11
LYNa Src 91.2 25
FGR Src 92.6 26
LCK Src 97.5 29
HCK Src 87.0 49
ABL Abl 90.7 45
FLT3 PDGFR 82.5 90
CSK Csk 8.6 ND
EGFR EGFR  8.5 ND
EPHB4 Eph 19.3 ND
FGFR1 FGFR 4.8 ND
IGF1R InsR 12.0 ND
ITK Tec 8.5 ND
KDR VEGFR  2.2 ND
MET Met  8.7 ND
PDGFRa PDGFR 6.3 ND
RET Ret 51.2 ND
TIE2 Tie  0.1 ND
TYRO3 Axl  6.9 ND
ZAP70 Syk 16.4 ND
Abbreviations: ABL, abelson; JAK, Janus kinase; ND, not done.
The ability of NS-018 to inhibit 23 tyrosine kinases was tested at one
concentration (100nM) in the presence of ATP at concentrations close
to their respective Km values. IC50 values were separately determined
against the kinase, which were shown to be inhibited 4 80% at
100nM NS-018.
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anemia, hepatosplenomegaly with extramedullary hemato-
poiesis, megakaryocyte hyperplasia and ﬁbrosis in the bone
marrow.
15 They also exhibit body weight loss and high mortality
compared with wild-type controls. Their bone marrow cells
show constitutive activation of STAT5 and cytokine-indepen-
dent erythroid colony formation. In this study, we tested the
efﬁcacy of NS-018 in this chronic MPN model. Before starting
long-term administration, we conﬁrmed that NS-018 inhibited
constitutive JAK2-mediated signaling in vivo. As expected,
NS-018 inhibited the phosphorylation of STAT5 in Mac1
þ/
Gr1
þ myeloid cells from bone marrow of V617F-TG mice
following a single oral administration at a dosage of 50mg/kg
(Supplementary Figure 1).
After disease was established at 12 weeks after birth, V617F-
TG mice were randomly assigned to treatment with NS-018 or
vehicle. NS-018 was administered by oral gavage twice a day
for 24 weeks at doses of 25 or 50mg/kg, and the control groups
received vehicle only. No signs of gross toxicity were observed
during the 24 weeks of treatment.
During the study, the peripheral blood count of the mice was
monitored monthly (Figures 5A–D). V617F-TG mice showed
marked leukocytosis. After 4 weeks of NS-018 treatment, the
WBC count was reduced to 59% in the 25mg/kg per group and
39% in the 50mg/kg per group compared with the vehicle-
treated group, and the effect was maintained until the end of the
study (Figure 5A). To determine which kinds of WBC increased,
we performed a fractional analysis by ﬂow cytometry. At 8
weeks, the numbers of Mac1
þ/Gr1
þ myeloid cells, B220
þ B
cells and CD3
þ T-cells in V617F-TG mice were respectively
370-, 5.4- and 8.8-fold greater than in wild-type (WT) mice
(Figure 5B). In the 50mg/kg per group, the respective numbers
fell to 98-, 3.3- and 5.3-fold. Although NS-018 reduced the
numbers of all WBC types, the reduction in Mac1
þ/Gr1
þ
myeloid cells was the greatest. V617F-TG mice also showed
progressive anemia (Figure 5C). The 25mg/kg per group
followed the same course of reduction in red blood cell count
as the vehicle-treated group. However, the 50mg/kg per group
Figure 2 Inhibition of JAK2-mediated signaling and induction of apoptosis in Ba/F3-JAK2V617F cells by NS-018. (a) Ba/F3-JAK2V617F cells were
treated with increasing concentrations of NS-018 for 3h and then lysed. Lysate was subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred to a Polyvinylidene ﬂuoride membrane and probed with the indicated antibodies. (b) Ba/F3-JAK2V617F cells were
treated with 0–300nM NS-018 for 48h and tested for apoptosis by staining with annexin V/propidium iodide (PI). (c) Ba/F3-JAK2V617F cells were
treated with NS-018 for 29h before DNA extraction and DNA fragmentation was assessed by agarose gel electrophoresis. M indicates the DNA
size marker.
Table 3 Antiproliferative activity of NS-018 against hematopoietic
cell lines
Cell line Origin Activated
kinase
IC50,
nm
Ba/F3-JAK2V617F Murine pro-B cell JAK2V617F 60
Ba/F3-TEL-JAK2 Murine pro-B cell TEL-JAK2 11
Ba/F3-TEL-JAK3 Murine pro-B cell TEL-JAK3 800
Ba/F3-MPLW515L Murine pro-B cell MPLW515L 61
SET-2 ET JAK2V617F 120
CMK AML JAK3A572V 1100
K-562 CML BCR-ABL 1600
MV4-11 AML FLT3-ITD 730
SKM-1 AML NK 4100
U-937 Lymphoma NK 5800
Abbreviations: AML, acute myelogenous leukemia; BCR-ABL, break-
point cluster region-abelson leukemia virus; CML, chronic myelogen-
ous leukemia; ET, essential thrombocythemia; FLT3-ITD, fms-like
tyrosine kinase 3-internal tandem duplication; MPL, myeloprolifera-
tive leukemia virus oncogene; NK, not known; TEL, translocation ets
leukemia.
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20 weeks, although the count was lower than that of WT mice.
This indicated that treatment with 50mg/kg NS-018 prevented
the progression of anemia. V617F-TG mice showed thrombo-
cytosis in the early stages, but the platelet (PLT) count declined
with time (Figure 5D). PLT aggregation and giant PLTs were
observed in the peripheral blood of these mice.
15 NS-018
treatment resulted in sustained thrombocytosis.
NS-018 treatment also reduced hepatosplenomegaly in a
dose-dependent manner (Figure 5E). In the spleen, NS-018
treatment signiﬁcantly decreased Mac1
þ/Gr1
þ myeloid cells
associated with extramedullary hematopoiesis and signiﬁcantly
increased B220
þ B cells (Figure 5F). Consistent with the
reduction in organ weights and inﬁltrating myeloid cells, the
histopathological results showed that NS-018 markedly reduced
cell invasion and restored normal architecture (Figure 5G). In
the spleen of V617F-TG mice, the white pulp was blended
throughout and partially preserved, and the red pulp was
expanded by mainly myeloid cell invasion. However, NS-018
treatment resulted in a marked reduction in cell invasion and a
restored architecture of the spleen (Figures 5Ga–d). In the liver
and lung, extramedullary hematopoiesis consisting of myeloid
cells and megakaryocytes was reduced in a dose-dependent
manner (Figures 5Ge–l) and almost completely disappeared in
the 50mg/kg per group (Figures 5Gh and l). In contrast to the
pathological improvement in these organs, NS-018 treatment
had little impact on the progression of ﬁbrosis and megakar-
yocyte hyperplasia in the bone marrow.
NS-018 improves survival and compromised nutritional
status in a mouse MPN model
V617F-TG mice exhibited reduced body weight gain and high
mortality compared with wild-type controls (Figures 5H and J).
However, mice treated with 50mg/kg NS-018 progressively
gained more weight than vehicle-treated mice, and their body
weight was comparable to that of WT mice (Figure 5H). Total
cholesterol was signiﬁcantly decreased in the serum of V617F-
TG mice compared with WT mice, indicating compromised
nutritional status. However, in accordance with the body weight
gain, the total cholesterol was increased in the NS-018-treated
groups at the end of the study (Figure 5I). NS-018 also improved
the survival of V617F-TG mice. During the 24-week study, 12 of
34 mice died in the vehicle group, whereas 1 of 36 mice died in
Figure 3 Effect of NS-018 on erythroid colony formation by PV
patient cells. Mononuclear cells isolated from the peripheral blood of
PV patients with the JAK2V617F mutation (n¼4) or healthy volunteers
(n¼3) were treated with increasing concentrations of NS-018 in
methylcellulose-based media with erythropoietin (a) or without
erythropoietin (b). BFU-Es were counted on day 14. Values represent
the mean±s.e.m. Statistical signiﬁcance was assessed by the t-test
(*Po0.05).
Figure 4 Effect of NS-018 on survival and splenomegaly in a mouse
Ba/F3-JAK2V617F disease model. Disease was established in BALB/c
nude mice by intravenous injection of 1 10
6 Ba/F3-JAK2V617F cells.
(a) Survival curves. NS-018 was administered by oral gavage twice a
day for 11 days at the indicated doses. Statistical signiﬁcance was
assessed by the log-rank test (*Po0.01 vs vehicle, eight mice per
group). (b) Mice inoculated with Ba/F3-JAK2V617F were orally
administered with the indicated doses of NS-018 twice a day.
Uninoculated control mice (sham) received vehicle only. The day
after the completion of 8 days of administration, spleens were
removed and weighed. Values represent the mean±s.e.m. Statistical
signiﬁcance was assessed by the t-test (
#Po0.01 vs sham) and
Dunnett’s test (*Po0.01 vs vehicle, ﬁve mice per group).
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statistically signiﬁcant prolongation of survival in the 50mg/kg
per group (Po0.01). Taken together, these results suggest
that NS-018 reduced leukocytosis, anemia progression, hepato-
splenomegaly and extramedullary hematopoiesis, improved
nutritional status, and prolonged survival in V617F-TG mice.
Discussion
In view of the lack of satisfying treatment options for patients
with BCR-ABL-negative MPNs, we sought to develop an
orally bioavailable small-molecule therapeutic agent to
treat these diseases. The discovery of the JAK2V617F and
MPLW515L mutations in MPN patients suggests that the
inhibition of aberrant JAK2 activation would have a thera-
peutic beneﬁt for MPN patients. Our novel JAK2 inhibitor,
NS-018, was found to be highly active against JAK2 with an
IC50 of o1n M and to have high selectivity for JAK2 over
many other kinases.
In addition to JAK2, NS-018 inhibited Src-family and ABL
kinases with up to almost 50-fold selectivity for JAK2 (Table 2).
To investigate the structural factors determining the selectivity of
NS-018, we carefully explored the binding site of the X-ray co-
crystal structure of the complex of the human JAK2 kinase
domain and NS-018 (Figure 1). Gly at position 993, which is
located immediately N-terminal to the A-loop DFG motif, tightly
ﬁxed the position of NS-018. Because Gly is the smallest amino
acid, we hypothesized that NS-018 effectively inhibites kinases
with small amino acids at this position. In keeping with this
hypothesis, NS-018 was active against ABL and Src-family
kinases, which have Ala, the second smallest natural amino
acid, at this position.
28 However, kinases belonging to the Axl,
FGFR, InsR, Met and Tie families have Gly or Ala at this
position, yet NS-018 did not inhibit them. These kinases may
have amino acids at other positions that prevent NS-018
Figure 5 Effect of NS-018 in JAK2V617F transgenic mice. JAK2V617F transgenic mice (TG) were divided into three groups and orally
administered with vehicle, 25mg/kg NS-018, or 50mg/kg NS-018 (n¼34, 37, and 36, respectively) twice a day for 24 weeks. Wild-type mice
(WT) received vehicle only (n¼27). (A) White blood cell (WBC), (C) red blood cell (RBC) and (D) platelet (PLT) counts were monitored monthly.
Values represent the mean±s.e.m. Statistical signiﬁcance was assessed by the t-test (*Po0.05, **Po0.01 vs TG vehicle). (B) Differences in cellular
composition. Nucleated cells from peripheral blood were stained with ﬂuorescently conjugated antibodies speciﬁc for Mac1/Gr1 (myeloid cells),
B220 (B cells) and CD3 (T-cells) and analyzed by ﬂow cytometry. (E) The weight of liver and spleen were measured at the end of the treatment
period. Values represent the mean±s.e.m. Statistical signiﬁcance was assessed by the t-test (
#Po0.01 vs WT vehicle) or Dunnett’s test (*Po0.05,
**Po0.01 vs TG vehicle). (F) Spleen cells were stained with ﬂuorescently conjugated antibodies speciﬁc for Mac1/Gr1 (myeloid cells), B220
(B cells) and CD3 (T-cells) and analyzed by ﬂow cytometry. (G) After NS-018 treatment, tissue sections were prepared from spleen (a–d; original
magniﬁcation  40), liver (e–h; magniﬁcation 200) and lung (i–l; magniﬁcation  200) for staining with hematoxylin and eosin. (H) The body
weight of the mice was monitored weekly. (I) The total cholesterol in the serum at the end of the study. Values represent the mean±s.e.m.
Statistical signiﬁcance was assessed by the t-test (
#Po0.01 vs WT vehicle) or Dunnett’s test (*Po0.01 vs TG vehicle). (J) Survival curves of mice.
Statistical signiﬁcance was assessed by the log-rank test (
#Po0.01 vs WT vehicle, *Po0.01 vs TG vehicle).
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amino acids such as Cys, Ser or Thr at this position, and NS-018
did not inhibit these kinases. Furthermore, the Ser/Thr kinases
listed in Supplementary Table 1 also have larger amino acids
such as Cys, Ser, Thr, Val, Leu or Ile at the corresponding
position, and NS-018 also did not inhibit these kinases. These
results provide evidence that the selectivity of NS-018 is largely
determined by the size of the amino acid at position 993.
JAK and Src-family kinases work in concert to activate many
signaling molecules.
29 Cooperation between SRC and JAKs is
required for full activation of STAT3.
30 Potent inhibition of
STAT3 phosphorylation in Ba/F3-JAK2V617F cells by NS-018
(Figure 2a) may be explained by the simultaneous inhibition
of JAK2 and Src-family kinases. Several reports have indicated
the involvement of Src-family kinases in the pathogenesis of
MPNs. For example, a TEL-lyn fusion gene has been identiﬁed in
a patient with primary myeloﬁbrosis.
31 The Src-family kinase
inhibitors dasatinib and PP2 have been shown to suppress
erythropoietin-independent erythroid colony growth from
PV.
32,33 Furthermore, SRC kinase preactivation is associated
with PLT hypersensitivity in essential thrombocythemia and PV
patient samples.
34 On the other hand, LYN, FGR and HCK have
been reported to be independent of JAK2V617F-induced poly-
cythemia in a murine retroviral bone marrow transplantation
model.
12 Although the involvement of Src-family kinases in
MPNs has not yet been fully clariﬁed, simultaneous inhibition of
JAK2 and some Src-family kinases is expected to be advanta-
geous in preventing aberrant JAK2-STAT signaling and thereby
curing the disease.
NS-018 inhibited the growth of cells, which depended on
JAK2 activation with IC50 values of 11–120nM. Consistent with
the selective inhibition by NS-018 of the enzymatic activity of
Figure 5 Continued.
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cells were less sensitive to NS-018. Weak inhibition of ABL
and FLT3 kinases by NS-018 is the most likely explanation for
its weak antiproliferative activity against K-562 cells (which
express BCR-ABL) and MV4-11 cells (which express an internal
tandem duplication of FLT3). The difference between the
selectivity of NS-018 in the enzyme-inhibition assay and in
the cell growth assay may arise from a difference in the extent to
which cell growth depends on kinase activation in these cell
lines. The fact that NS-018 did not inhibit other Tyr or Ser/Thr
kinases might explain its low general cytotoxicity against
nontarget cells.
The efﬁcacy of several JAK2 inhibitors has been evaluated in
an acute mouse Ba/F3-JAK2V617F disease model.
35–37 In this
study, NS-018 seemed as effective as these inhibitors in this
model (Figure 4). These results demonstrate the in vivo potency
of NS-018. To further evaluate the efﬁcacy of NS-018 in a
chronic MPN model, we performed long-term administration
of NS-018 to transgenic mice expressing JAK2V617F. In contrast
to other reports that several JAK2V617F transgenic mice tend
to show polycythemia,
13,14,16–18 our transgenic mice showed
progressive anemia.
15 Although the reason for this is unclear,
any impairments in the differentiation of erythrocyte progenitors
to mature erythrocytes and the progression of bone marrow
ﬁbrosis are supposed to be related to anemia (unpublished data).
Treatment with 50mg/kg NS-018 prevented the progression
of anemia in these mice (Figure 5C). To assess the causes of
differences in the peripheral blood count, we examined the
effects of NS-018 on hematopoietic cellular compartments
and differentiation in bone marrow and spleen by ﬂow
cytometric analysis. No signiﬁcant differences were observed
in the proportion of hematopoietic stem cells (CD34
þ/Kit
þ/
Sca1
þ/Lineage
 ), common myeloid progenitors (CD34
þ/Kit
þ/
Sca1
 /FcgR
low/Lineage
 ), granulocyte/macrophage progeni-
tors (CD34
þ/Kit
þ/Sca1
 /FcgR
high/Lineage
 ), megakaryocytic/
erythroid progenitors (CD34
low/Kit
þ/Sca1
 /FcgR
low/Lineage
 ),
erythrocyte progenitors (CD71
þ/Ter119
þ) or megakaryocytic
progenitors (CD41
þ/Kit
þ/CD9
þ/FcgR
low/Lineage
 ) in the
NS-018-treated group compared with the vehicle-treated group
(data not shown). Because the proportions of stem cells and
progenitors in the spleen and bone marrow were not changed
by NS-018 administration, it was assumed that erythrocyte
progenitors did not increase. Additionally, serum levels of
erythropoietin and thrombopoietin were not signiﬁcantly
different in NS-018-treated and vehicle-treated V617F-TG mice.
Thus, the reason for the NS-018-dependent reduction in anemia
progression remains unclear.
V617F-TG mice also showed thrombocytosis in the early
stages, but the PLT count slowly decreased with time. Because
the megakaryocyte number in bone marrow in these mice was
remained higher than in WT mice, PLT production was assumed
not to have decreased. One possible explanation for the
reduction in PLT count is enhancement of PLT trapping due to
progressive splenomegaly. The sustained thrombocytosis caused
by NS-018 treatment (Figure 5D) was considered to be the result
of reduced splenomegaly. Another possible explanation for the
PLT-count reduction in V617F-TG mice is a reduced PLT life
span due to the enhanced PLT aggregation. It has been
hypothesized that, in patients with MPNs, continuous leukocyte
degranulation due to leukocyte activation might result in the
consumption of factor V and protein S, leading to activated
protein C resistance and increased risk of thrombosis.
38 PLT
aggregation has also been observed in V617F-TG mice.
15
Although NS-018 has been shown not to affect the clotting
function of blood from normal rats (unpublished data), treatment
with NS-018 might reduce PLT aggregation by suppressing
leukocyte activation, thereby prolong PLT life span in these
mice.
Loss of appetite and deterioration in nutritional status are
observed in patients with MPNs, especially myeloﬁbrosis.
39
V617F-TG mice also exhibited reduced body weight gain and
reduced total serum cholesterol levels, and NS-018 markedly
increased both their body weight gain and their cholesterol
levels (Figures 5H and I). These effects may have been brought
about by an improvement in appetite through a reduction in
the mechanical compression of the gastrointestinal tract result-
ing from hepatosplenomegaly, as well as inhibition of leptin
signaling through JAK2. Improvement in nutritional status by
NS-018 seemed to contribute to the prolonged survival of
these mice.
In summary, NS-018 signiﬁcantly reduced leukocytosis,
hepatosplenomegaly and extramedullary hematopoiesis, and
improved nutritional status in V617F-TG mice. All these effects
of NS-018 may contribute to the survival beneﬁts observed in
V617F-TG mice. Additionally, NS-018 inhibited erythroid
colony formation by peripheral blood mononuclear cells from
PV patients at concentrations signiﬁcantly lower than those
required for healthy controls (Figure 3). Examination of the
X-ray co-crystal structure showing NS-018 bound to JAK2 in the
‘DFG-in’ active conformation strongly suggests that NS-018 may
inhibit constitutively activated JAK2 with the V617F mutation
as well as or better than it inhibits activated wild-type JAK2.
Overall, our results suggest that NS-018 will be effective in
treating patients with MPNs. The efﬁcacy and safety of NS-018
for MPNs is expected to be veriﬁed by early-phase clinical trials
to begin in early 2011.
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